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with thoracic aortic pathology.1 Selection
of a control group that is perfectly matched
for ethnic ancestry with a group of affected
individuals is indeed a major challenge in
studying the associations between candi-
date genes and diseases. Not surprisingly,
most published studies have imperfectly
matched case-control populations. Never-
theless, the substantial geographic differ-
ence between our control and study popu-
lations clearly warrants discussion.
Although geographically diverse, white
populations from Australia and the United
States are genetically similar. The majority of
the white Australian population has ancestors
who, within only a few generations, origi-
nated from the European continent. Previous
studies of other genetic polymorphisms have
demonstrated great similarities between the
white Australian population and white sub-
jects residing on other continents.2,3 Our
American patients with thoracic aortic dis-
ease were classified as white with European
origin and therefore share a similar genetic
origin with white Australians. Although the
Australian and American populations have
resided on two different continents for a
number of generations, the migration and
constitutive establishment for both countries
date back only approximately 200 years. The
founder effect is generally small within such
a short period. Still, even within a given
white population, genetic admixture can be
large for certain genes. Because of this and
other inherent limitations, studies in separate
populations are required to confirm any sig-
nificant genetic associations observed from
one particular population.
Given the genetic similarities between
white Australians and white Americans (de-
spite the geographic difference), we chose
our control population for the absence of
angiographic evidence of proximal thoracic
aortic aneurysms or dissection. This reduced
the likelihood that control subjects had tho-
racic aortic disease, which would have con-
founded the comparisons with our patient
groups. To address at least somewhat the
issue of geographic diversity in our study,
we demonstrated that the frequencies of the
three MMP9 SNPs in our control group
were not significantly different from those
previously described by Applied Biosys-
tems (Foster City, Calif) in a white popu-
lation from the United States.1 The pres-
ence of Hardy-Weinberg equilibrium in the
control group is also reassuring; there
was no significant deviation from Hardy-
Weinberg equilibrium for the three MMP9
polymorphisms in the control group (P 
.81 for -8202A/G; P  .98 for IVS4 
3G/T; P  .93 for 2003A/G). No signifi-
cant deviation from Hardy-Weinberg equi-
librium was observed for IVS43G/T and
2003A/G in patients with thoracic aortic
aneurysms or dissection; a significant de-
viation from Hardy-Weinberg equilibrium
was observed for -8202A/G in our case
patients.
Recent publications have suggested the
existence of haplotype blocks. Haplotypes at
these blocks could serve as multiallelic mark-
ers in disease-association studies.4 Examin-
ing all observed haplotypes for associations,
rather than just those that are proxies for
known SNPs, increases power to detect rare
causal alleles, but at the cost of reduced
power to detect common causal alleles.
Furthermore, the haplotype-SNP– based
approach does not always have higher
power than the single-SNP–based study, as
is supported by theoretic considerations.
With the data collected in our population,
some linkage analysis can be conducted for
haplotype construction. Estimated haplo-
type frequencies cannot be treated as ob-
served data, however, and therefore there is
no valid statistical test for evaluating the
possible contribution of individual haplo-
types. Although testing haplotype blocks of
the MMP9 locus and surrounding regions
by including more SNPs might provide ad-
ditional information, the most effective
way to validate the findings reported in our
study is to confirm the association in other
case-control populations.
As with all genetic association stud-
ies, our study has limitations and the
findings should be interpreted cautiously.
Studies in separate populations will be
required to confirm the association that
we observed between the MMP9
-8202A/G polymorphism and thoracic
aortic aneurysms and dissection. We hope
that our data will stimulate expanded re-
search regarding the genetic aspects of tho-
racic aortic disease, particularly in patients
who do not have archetypal heritable disor-
ders such as Marfan syndrome. Our partici-
pation in the newly established Specialized
Center of Clinically Oriented Research in
Thoracic Aortic Aneurysms and Dissection
will provide exciting opportunities to per-
form such studies and expand our under-
standing of the genetic determinants that
underlie thoracic aortic disease.
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Placement of the Impella Recover LD
microaxial blood pump through a
bioprosthesis is technically feasible
To the Editor:
We read with great interest the article of
Strauch and colleagues1 regarding their ex-
perience with Impella Recover LD support
for postcardiotomy low-output syndrome in a
patient undergoing aortic valve replacement
with a bioprosthesis. In our initial experi-
ence2 we reported the use of the Impella
Recover LD to support a patient with valvu-
lar cardiomyopathy who underwent conven-
tional mitral valve repair and aortic valve
replacement with a 21 mm Carpentier-Ed-
wards bioprosthesis. Despite maximal ino-
tropic support (epinephrine dose, 0.2 g/
kg1/min1), the patient could not be
weaned from extracorporeal circulation,
with hypotension, increased filling pressure
(left atrial pressure, 28 mm Hg), and oli-
guria (urine output, 30 mL/h). The cal-
culated intra-aortic balloon pump (IABP)
score for the patient was 2, which predicts
a 52% 30-day mortality according to Haus-
mann and coworkers.3 The Impella LD
was then implanted with the standard tech-
nique and advanced in the left ventricle
through the prosthesis under echocardio-
graphic guidance. In our experience pass-
ing the biologic valve was not immediate
Letters to the Editor
The Journal of Thoracic and Cardiovascular Surgery ● Volume 132, Number 4 989
but requires some attempts. Transesophageal
echocardiography confirmed right pump
placement and no interference between
valve leaflet movements and outflow-tip
antegrade flow. A trivial aortic regurgita-
tion was detected, probably because of the
relative stiffness of prosthetic compared
with natural valve leaflets. The postopera-
tive course was characterized by persistent
oliguria that required central veno–venous
haemofiltration, with slow improvement of
cardiac function. Inotropic support was
continued for 6 days and then slowly de-
creased. After 15 days of support, the pa-
tient was weaned from the device and
discharged home. Follow-up echocardi-
ography showed markedly improved left
ventricular contractility and good perfor-
mance of the aortic valve without signs of
damage to the leaflets.4
We agree with the author that in the set-
ting of postcardiotomy heart failure, deciding
when to start a patient on mechanical support
without wasting any precious time is the key
to success. Recently, we have introduced in
our clinical practice the IABP score as a
very useful tool in the decision-making
process of mechanical support in postcar-
diotomy heart failure. Hausmann and col-
leagues3 defined an IABP score based on 4
parameters they found statistically signifi-
cant to predict survival or death 1 hour
after IABP implantation in patients with
low-output syndrome in cardiac surgery.
The Hausmann IABP score has been vali-
dated also by Siegenthaler and associates5
in their study of 24 patients supported with
the Impella LD for postcardiotomy heart
failure. In addition, they were able to iden-
tify patients who will not benefit from the
Impella Recover. Patients with a residual
cardiac function of 1 L/min or less had an
88% chance of death. This observation is
likely due to the fact that the Impella de-
vice provides insufficient support in the
presence of virtually absent myocardial
function.
In conclusion, we agree with the au-
thors that timely insertion of such a device
in the postcardiotomy setting, even in bor-
derline situations or after stented biologic
aortic valve prosthesis implantation, can
provide a greater chance of survival in a
poor-prognosis population. Careful clini-
cal, hemodynamic, and residual cardiac
function evaluation can allow surgeons
to stratify patients for prolonged IABP-
inotropic support or timely Impella implan-
tation or even to receive a conventional left
ventricular assist device if cardiac perfor-
mance is dismal.
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Off-pump pulmonary valve
implantation
To the Editor:
We would like to comment on the article
by Berdat and Carrel1 entitled “Off-pump
pulmonary valve replacement with the
new Shelhigh Injectable Stented Pulmonic
Valve.” They are to be congratulated for
having embarked on a novel approach.
Because we have also reported recently
on our first surgical experience implanting
the Shelhigh valve, 2 points should be made.2
First, it is misleading to report on a
pulmonary valve “replacement” in this set-
ting. All 4 patients from the mentioned
group had either undergone the transannu-
lar patch procedure during tetralogy of Fal-
lot repair or commissurotomy. Likewise,
we have also gained, to date, experience
with a total of 6 patients (mean follow-up,
7.8 months; range, 2.0-13.5 months). All of
these had previous tetralogy of Fallot re-
pair. Therefore use of the Shelhigh valve in
its current form allows only for valve “im-
plantation” because the stented valve can
only self-expand and the original pulmonary
valve apparatus remains obviously in situ.
Second, we disagree with the judgment
that a reduction plasty for an enlarged main
pulmonary trunk of larger than 28 mm is
mandatory to ensure an adequate position
of the stented valve. Berdat and Carrel1
made this statement on their experience
with 1 patient only. In our experience with
6 patients (valve sizes, 23-31 mm), periop-
erative assessment included the whole right
ventricular outflow tract, dimensions of the
right ventricle to pulmonary trunk junction,
sinus of Valsalva, pulmonary trunk, and
pulmonary bifurcation. Interestingly, the fi-
nal position of the stented valve was, in our
experience, at different sites: at the level of
the pulmonary valve, just above it, and
even much more distally just in front of the
bifurcation. Therefore we would rather em-
phasize the need for both transesophageal
and epicardial echocardiographic naviga-
tion and “oversizing” of at least 2 mm to
allow for a perfect fit of this new valve
along its struts.
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Reply to the Editor:
We appreciate the comments by Schre-
iber and Lange. We believe that making a
difference between “implantation” and
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